Fetuin-A in patients with metabolic syndrome
Current Issues in Pharmacy and Medical Sciences Vol. 26, No. 3, Pages 305-308
ANNA MARIA DĄBROWSKA1*, JERZY S.TARACH1, BEATA WOJTYSIAK-DUMA2,
ARLETA MALECHA-JĘDRASZEK2, ANNA TORUŃ-JURKOWSKA3, JANUSZ KUDLICKI4,
1 Department of Endocrinology, Medical University, Lublin, Poland
2 Department of Biochemical Diagnostics, Chair of Laboratory Diagnostics, Medical University, Lublin, Poland
3 Department of Mathematics and Medical Biostatistics, Medical University, Lublin, Poland
4 Department of Cardiology, Medical University, Lublin, Poland
Metabolic syndrome is a common disorder the prevalence of which is estimated to be about 20% in Polish adult population. Abdominal obesity and insulin resistance are important pathogenetic factors. Metabolic syndrome plays a role as a risk factor for type 2 diabetes and cardiovascular disease. Fetuin-A is a multifunctional plasma glycoprotein. It is a physiological inhibitor of insulin receptor tyrosine kinase and thus associated with insulin resistance, metabolic syndrome and an increased risk for type 2 diabetes. The study was conducted in 62 patients with metabolic syndrome (34F and 28M) aged 35-83. In 47 persons type 2 diabetes was a component of metabolic syndrome, 62% of diabetics had coronary artery disease as a macrovascular complication. Determinations of biochemical parameters and anthropometric measurements were performed in the studied group. We analysed a relationship between serum fetuin-A concentration and components of metabolic syndrome and total cholesterol, LDL-cholesterol, HbA1C, BMI as well. Diabetics had lower fetuin-A concentrations than patients without diabetes (0.550 g/l vs 0.600 g/l). Fetuin-A levels in patients with diabetes and coronary artery disease were significantly lower (0.535 g/l) than in those without macrovascular complications (0.590 g/l) (Z=1.969; p=0.048). Furthermore the correlation between fetuin-A serum
concentration and fasting plasma glucose, LDL-cholesterol and triglycerides levels were observed. Patients with higher fasting glucose had lower fetuin-A levels. However, fetuin-A concentration was positive correlated with LDL-cholesterol and triglycerides levels. No association between fetuin-A and waist circumference, blood pressure, HDL-cholesterol, HbA1C and BMI were found. In summary, serum fetuin-A level has a correlation with some components of metabolic syndrome. We concluded that fetuin-A could be used not only as a marker, but also plays some role in pathogenesis of metabolic syndrome, type 2 diabetes and higher risk of cardiovascular disease.
Files to download
fetuin-A, metabolic syndrome, type 2 diabetes
- Brix J.M., Stingl H., Hollerl F. et al. Elevated Fetuin-A concentrations in morbid obesity decrease after dramatic weight loss. J. Clin. Endocrinol. Metab., 95, 4877, 2010.
- Erdmann J., Salmhofer H., Knauß A. et al. Relationship of fetuin-A levels to weight-dependent insulin resistence and type 2 diabetes mellitus. Regul. Pept., 178, 6, 2012.
- Ismail N.A., Ragab S., Abd El Dayem S.M. et al. Fetuin A levels in obesity: differences in relation to metabolic syndrome and correlation with clinical and laboratory variables. Arch. Med. Sci., 5, 826, 2012.
- Ix J.H., Shlipak M.G., Brandenburg V.M. et al. Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation, 113, 1760, 2006.
- Ix J.H., Wassel C.L., Kanaya A.M. et al. Fetuin-A and incident diabetes mellitus in older persons. JAMA, 300, 182, 2008.
- Jahnen-Dechent W., Heiss A., Schäfer C. et al. Fetuin-A regulation of calcified matrix metabolism. Circ. Res., 108, 1494, 2011.
- Kaushik S.V., Plaisance E.P., Kim T. et al. Extended-release niacin decreases serum fetuin-A concentrations in indivuduals with metabolic syndrome. Diabetes. Metab. Res. Rev., 25, 427, 2009.
- Reinehr T., Roth C.L. Fetuin-A and its relation to metabolit syndrome and fatty liver disease in obese children before and after weight loss. J. Clin. Endocrinol. Metab., 93, 4479, 2008.
- Sieradzki J. (2010). Cukrzyca i zespół metaboliczny. In: Choroby wewnętrzne. Stan wiedzy na rok 2010. Szczeklik A. (editor). Kraków: Medycyna Praktyczna; p. 1283.
- Singh M., Sharma P.K., Garg V.K. et al. Role of fetuin-A in atherosclerosis associated with diabetic patients. J. Pharm. Pharmacol., 64, 1703, 2012.
- Stefan N., Fritsche A., Weikert C. et al. Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes, 57, 2762, 2008.
- Stefan N., Hennige A.M., Steiger H. et al. α2-Heremans-Schmid Glycoprotein/Fetuin-A is associated with insulin resistence and fat accumulation in the liver in humans. Diabetes Care, 29, 853, 2006.
- Vörös K., Gráf L. Jr., Prohászka Z. et al. Serum fetuin-A inmetabolic and inflammatory pathways in patients with myocardial infarction. Eur. J. Clin. Invest., 41, 703, 2011.
- Wojtysiak-Duma B., Malecha Jędraszek A., Burska A. et al. Serum fetuiny-A levels in patients with type 2 diabetes mellitus. Ann. UMCS Sect. DDD, 2, 93, 2010.
- Xu Y., Xu M., Bi Y. et al. Serum fetuin-a is corretaled with metabolic syndrome in middle-aged and elderly Chinese. Atherosclerosis, 216, 180, 2011.